Exploring Updates on AMPLIFY at ASH 2024

Opinion
Video

Experts examine both overall survival outcomes and independent review committee–assessed progression-free survival data from the AMPLIFY trial.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay up to date on practice-changing data in community practice.

      Subscribe Now!
      Recent Videos
      Case 3 (cont.): Management of Treatment-Associated ILD/Pneumonitis
      Case 3 (cont.): Management of Treatment-Associated ILD/Pneumonitis
      Management of ADC-Related AEs
      Management of ADC-Related AEs
      Seymour on the BCL-2 Pathway and Novel Therapeutic Strategies in CLL
      Seymour on the BCL-2 Pathway and Novel Therapeutic Strategies in CLL
      1 expert is featured in this series.
      Current Practices and Initial Treatment Considerations for Patients With cGVHD
      DLBCL Subtype Response Patterns: Optimizing Treatment Selection
      DLBCL Subtype Response Patterns: Optimizing Treatment Selection
      Evolving Treatment Strategies in DLBCL: Real-World Clinical Experience
      Evolving Treatment Strategies in DLBCL: Real-World Clinical Experience
      2 experts in this video
      The Evolving Role of Lenvatinib in the HCC Therapeutic Landscape
      2 experts in this video
      Second-Line Therapy in Advanced HCC: Treatment Considerations and Evolving Options
      HER2-Mutated NSCLC: Second-Line Treatment Selection and Emerging Approaches
      HER2-Mutated NSCLC: Second-Line Treatment Selection and Emerging Approaches
      HER2 Mutations in NSCLC
      HER2 Mutations in NSCLC
      Related Content
      Incorporating MRD into Monitoring After Fixed-Duration CLL Treatment

      Incorporating MRD into Monitoring After Fixed-Duration CLL Treatment

      Targeted Oncology Staff
      April 7th 2025
      Article

      During a Case-Based Roundtable® event, John N. Allan, MD, discussed the addition of anti-CD20 antibody and the use of MRD following fixed-duration treatment of chronic lymphocytic leukemia.

      Read More

      Understanding the Role of Zanubrutinib for the Treatment of CLL

      Understanding the Role of Zanubrutinib for the Treatment of CLL

      Rohit Gosain, MD;Rahul Gosain, MD
      April 23rd 2024
      Podcast

      Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

      Listen

      Jacobs and Peers Consider Third-Line Treatment in Relapsed/Refractory CLL

      Jacobs and Peers Consider Third-Line Treatment in Relapsed/Refractory CLL

      Targeted Oncology Staff
      March 14th 2025
      Article

      During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for chronic lymphocytic leukemia.

      Read More

      Exciting Activity in Chronic Lymphocytic Leukemia

      Exciting Activity in Chronic Lymphocytic Leukemia

      Nichole Tucker;Cyrus M. Khan, MD
      May 31st 2023
      Podcast

      In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

      Listen

      Jain and Participants Consider BTK Inhibitor Resistance in CLL

      Jain and Participants Consider BTK Inhibitor Resistance in CLL

      Targeted Oncology Staff
      February 13th 2025
      Article

      During a Case-Based Roundtable® event, Nitin Jain, MD, and participants discussed treating a patient with CLL after acalabrutinib and venetoclax/rituximab.

      Read More

      Selection of Next-Gen BTK in CLL Limited By Lack of Direct Comparison

      Selection of Next-Gen BTK in CLL Limited By Lack of Direct Comparison

      Targeted Oncology Staff
      February 4th 2025
      Article

      During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK inhibitor therapies acalabrutinib and zanubrutinib in patients with chronic lymphocytic leukemia who received 1 prior line of therapy in the second article of a 2-part series.

      Read More